Acino Holding AG
Latest From Acino Holding AG
Top China executives from Pfizer, AstraZeneca, GSK share their views on growing in China amid lingering challenges despite regulatory progress.
Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.
Ambitious and confident Chinese pharmaceutical buyers have begun to enter a new brave world of foreign M&A. However, this scenario can be littered with internal challenges and increasingly external scrutiny, less solid pre-deal asset identification and poor post-deal execution, all of which can damage their barely gained credibility, creating hurdles for future deals.
Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.
- Contract Research, Toxicology Testing-CRO
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Acino Pharma Ltd.
- Western Europe
- Parent & Subsidiaries
- Acino Holding AG
- Senior Management
Peter Burema, CEO
Martin Gertsch, CFO
Jean-Daniel Bonny, PhD, Head, R&D
Ruud van Anraat, Chief Commercial Officer
- Contact Info
Acino Holding AG
Phone: 61 338 60 00
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.